Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis - Abstract

Harold Hopkins Department of Urology, Royal Berkshire Hospital, Reading and Nuffield, UK.

We determined the role of factor inhibiting hypoxia-inducible factor-1 in prostate cancer specimens.

A tissue microarray of 152 prostate cancers was constructed and stained for factor inhibiting hypoxia-inducible factor-1, hypoxia-inducible factor-1α and 2α, and glucose transporter 1 as a prototypical downstream target of hypoxia-inducible factor-1α. Correlation analysis was done between these variables, and between factor inhibiting hypoxia-inducible factor-1, and clinical and pathological variables, including prostate specific antigen as a surrogate of recurrence.

Factor inhibiting hypoxia-inducible factor-1 was expressed in the cytoplasm and/or the nucleus in 86.5% of tumors, including exclusive cytoplasmic expression in 51.3% and exclusive nuclear expression in 5.3%. Any nuclear and exclusive expression of factor inhibiting hypoxia-inducible factor was associated with poor prognosis on univariate analysis (p = 0.007 and 0.042, respectively). On multivariate analysis men with nuclear expression in tumors were twice as likely to experience recurrence (p = 0.034).

Factor inhibiting hypoxia-inducible factor-1 is widely expressed in prostate tumors. Its differential subcellular expression suggests that regulation of its expression is an important factor in the activity of the hypoxia-inducible factor pathway. Its modulation may help treat hypoxia-inducible factor driven aggressive prostate cancer.

Written by:
Shaida N, Chan P, Turley H, Jones CM, Kanga S, Ritchie RW, Malone PR, Harris AL, Fox SB.   Are you the author?

Reference: J Urol. 2011 Feb 18. Epub ahead of print.
doi: 10.1016/j.juro.2010.12.001

PubMed Abstract
PMID: 21334674

UroToday.com Prostate Cancer Section

email news signup